Hoth Therapeutics Inc (NASDAQ:HOTH), a US-based clinical-stage biopharmaceutical company, announced on Thursday that it has achieved a major European regulatory milestone for its HT-001 clinical programme, targeting cancer patients undergoing EGFR inhibitor therapies.

The company has received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I. The company says that this determination confirms the scientific and regulatory acceptability of the trial design and investigational products. Hoth expects to activate clinical trial sites and initiate the study across multiple European countries.

HT-001 is being developed to deal with EGFRI-induced dermatologic toxicities, a common and often dose-limiting complication experienced by cancer patients undergoing treatment. These side effects can negatively impact quality of life, disrupt treatment schedules, and increase overall healthcare burden.

Hoth aims to activate sites, initiate patient enrolment, and advance the programme into active clinical execution, representing a critical step toward validating a potential new supportive-care therapy for oncology patients.